{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:19Z","timestamp":1772166439712,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T00:00:00Z","timestamp":1702771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"crossref","award":["Z-2018-35-2002"],"award-info":[{"award-number":["Z-2018-35-2002"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Foundation of third Affiliated Hospital of Sun Yat-sen University","award":["YHJH201904"],"award-info":[{"award-number":["YHJH201904"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute-on-chronic liver failure (ACLF) is a common clinical type of liver failure, and patients with acute-on-chronic liver failure are prone to fungal infections, especially the increasing incidence of invasive pulmonary aspergillosis (IPA). Voriconazole is recommended as the first-line antifungal agent in the treatment of invasive aspergillosis; however, no recommendation has been given for patients with severe liver cirrhosis (Child\u2013Pugh C) and liver failure. This trial aims to examine the therapeutic effects and safety of voriconazole in the treatment of IPA in patients with liver failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a non-double-blind randomized controlled trial. The 96 eligible acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis will be randomly assigned to receive either the optimized voriconazole regimen or the recommended voriconazole regimen for patients with mild to moderate liver cirrhosis (Child\u2013Pugh A and B), at a 1:1 ratio, with an 8-week follow-up period. The antifungal efficacy of voriconazole will be the primary outcome measure. Plasma voriconazole trough concentration, the laboratory examination (CRP, PCT, ESR, etc.), chest CT, adverse events, and mortality at week 4 and 8 will be the secondary outcome measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial aims to demonstrate the efficacy and safety of voriconazole in the treatment of IPA in patients with liver failure, which is expected to provide a reference for scientific optimization of voriconazole regimens and a realistic basis for the standardized treatment of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>The trial was registered with the Chinese Clinical Trial Registry, ChiCTR2100048259. Registered on 5 July 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-023-07755-6","type":"journal-article","created":{"date-parts":[[2023,12,17]],"date-time":"2023-12-17T08:02:18Z","timestamp":1702800138000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of voriconazole in the treatment of invasive pulmonary aspergillosis in patients with liver failure: study protocol for a randomized controlled clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Xue","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lejia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziying","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihua","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-4344","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,17]]},"reference":[{"key":"7755_CR1","first-page":"1","volume-title":"Acute Exacerbation of Chronic Hepatitis B","author":"N Qin","year":"2019","unstructured":"Qin N, Wu D, Guo W. Introduction to acute exacerbation of chronic hepatitis B (AECHB). In: Qin N, editor. Acute Exacerbation of Chronic Hepatitis B. Wuhan: Professor; 2019. p. 1\u201314."},{"issue":"12","key":"7755_CR2","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.7150\/ijms.6824","volume":"10","author":"J Chen","year":"2013","unstructured":"Chen J, Yang Q, Huang J, et al. Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study. Int J Med Sci. 2013;10(12):1625\u201331.","journal-title":"Int J Med Sci"},{"issue":"5","key":"7755_CR3","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1177\/030006051204000537","volume":"40","author":"Z Wu","year":"2012","unstructured":"Wu Z, Ling Z, Shao F, et al. Invasive pulmonary aspergillosis in patients with acute-on-chronic liver failure. J Int Med Res. 2012;40(5):1958\u201365.","journal-title":"J Int Med Res"},{"issue":"5","key":"7755_CR4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10096-010-1137-2","volume":"30","author":"W Wang","year":"2011","unstructured":"Wang W, Zhao CY, Zhou JY, et al. Invasive pulmonary aspergillosis in patients with HBV-related liver failure. Eur J Clin Microbiol Infect Dis. 2011;30(5):661\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"7755_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jhep.2013.09.011","volume":"60","author":"T Gustot","year":"2014","unstructured":"Gustot T, Maillart E, Bocci M, et al. Invasive aspergillosis in patients with severe alcoholic hepatitis. J Hepatol. 2014;60(2):267\u201374.","journal-title":"J Hepatol"},{"issue":"4","key":"7755_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and Management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1\u201360.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"7755_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41598-018-19320-2","volume":"8","author":"J Gao","year":"2018","unstructured":"Gao J, Zhang Q, Wu Y, et al. Improving survival of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis. Sci Rep. 2018;8(1):876.","journal-title":"Sci Rep"},{"issue":"1","key":"7755_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bcp.12182","volume":"77","author":"A Albarmawi","year":"2014","unstructured":"Albarmawi A, Czock D, Gauss A, et al. CYP3A activity in severe liver cirrhosis correlates with Child-Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol. 2014;77(1):160\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"7755_CR9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/cc11218","volume":"16","author":"M Bernardi","year":"2012","unstructured":"Bernardi M, Maggioli C, Zaccherini G. Human albumin in the management of complications of liver cirrhosis. Crit Care. 2012;16(2):211.","journal-title":"Crit Care"},{"issue":"1","key":"7755_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/bcpt.13208","volume":"125","author":"D Tang","year":"2019","unstructured":"Tang D, Song BL, Yan M, et al. Identifying factors affecting the pharmacokinetics of voriconazole in patients with liver dysfunction: a population pharmacokinetic approach. Basic Clin Pharmacol Toxicol. 2019;125(1):34\u201343.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"7755_CR11","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1016\/j.xphs.2019.09.019","volume":"108","author":"QX Ren","year":"2019","unstructured":"Ren QX, Li XG, Mu JS, et al. Population pharmacokinetics of voriconazole and optimization of dosage regimens based on Monte Carlo simulation in patients with liver cirrhosis. J Pharm Sci. 2019;108(12):3923\u201331.","journal-title":"J Pharm Sci."},{"issue":"3","key":"7755_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"7755_CR13","doi-asserted-by":"publisher","unstructured":"Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association, Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for diagnosis and treatment of liver failure (2018). Chin J Hepatol. 2019;(01):18\u201326. https:\/\/doi.org\/10.3760\/cma.j.issn.1000-6680.2019.01.001.","DOI":"10.3760\/cma.j.issn.1000-6680.2019.01.001"},{"issue":"12","key":"7755_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of cancer\/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases mycoses study group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"7755_CR15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"7755_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","volume":"347","author":"R Herbrecht","year":"2002","unstructured":"Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"7755_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1086\/324620","volume":"34","author":"DW Denning","year":"2002","unstructured":"Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563\u201371 (Epub 2002 Jan 22 PMID: 11807679).","journal-title":"Clin Infect Dis"},{"key":"7755_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ijid.2018.05.009","volume":"72","author":"T Wang","year":"2018","unstructured":"Wang T, Yan M, Tang D, et al. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: a multicenter study. Int J Infect Dis. 2018;72:49\u201354.","journal-title":"Int J Infect Dis"},{"issue":"Suppl 1","key":"7755_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;56(Suppl 1):2\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"7755_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0002-9343(94)90023-X","volume":"97","author":"DW Denning","year":"1994","unstructured":"Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97(2):135\u201344.","journal-title":"Am J Med"},{"key":"7755_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","volume":"47","author":"HS Brahm","year":"2008","unstructured":"Brahm HS, Raoul H, David AS. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: mycoses study group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674\u201383.","journal-title":"Clin Infect Dis"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07755-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07755-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T12:04:17Z","timestamp":1703073857000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07755-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,17]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7755"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07755-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1525562\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,17]]},"assertion":[{"value":"13 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, informed consent form, and other submitted documents were reviewed and approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-Sen University for Human Study (reference number [2021] 02\u2013114-01). The trial registration number is ChiCTR2100048259 (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"Not applicable\u2014no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"811"}}